Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Monday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 20th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Price Performance

Shares of NASDAQ:EPRX opened at $3.33 on Monday. The stock has a market capitalization of $118.67 million and a P/E ratio of -4.62. The business has a 50-day moving average of $3.53 and a two-hundred day moving average of $3.14. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $4.48.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Eupraxia Pharmaceuticals in a research report on Friday, February 21st. They set a “buy” rating and a $12.00 target price for the company.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.